Madhusmita Behera1, Camille Ragin2, Sungjin Kim3, Rathi N Pillai1, Zhengjia Chen4, Conor E Steuer1, Nabil F Saba1, Chandra P Belani5, Fadlo R Khuri1,4, Suresh S Ramalingam1,4, Taofeek K Owonikoko1,4. 1. Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia. 2. Cancer Prevention and Control Program, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania. 3. Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California. 4. Biostatistics Core, Winship Cancer Institute, Emory University, Atlanta, Georgia. 5. Penn State Hershey Cancer Institute, Hershey, Pennsylvania.
Abstract
BACKGROUND: The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS: There were 47,351 eligible patients: 52% were male; the median age was 71 years; and 87% were white, 7% were black, and 1.4% were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38%, 55%, 50%, and 53%; P < .001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51%), Asians (53%), and rural residents (60%) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P < .001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P = .005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P < .001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P = .875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P < .001). CONCLUSIONS: Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting.
BACKGROUND: The last 3 decades have witnessed limited therapeutic advances in small cell lung cancer (SCLC) management. This study evaluated real-world trends in the use of systemic therapies and the impact on patient outcomes in the United States. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to find patients diagnosed with SCLC between 1985 and 2005. The 1985-1990 period served as the baseline for a temporal analysis conducted at 5-year intervals (1985-1990, 1991-1995, 1996-2000, and 2001-2005). Cox proportional models were used to estimate the effect of chemotherapy on survival. Results were validated with a propensity-matched analysis. RESULTS: There were 47,351 eligible patients: 52% were male; the median age was 71 years; and 87% were white, 7% were black, and 1.4% were Asian. The proportion of patients treated with chemotherapy was low but increased over time (38%, 55%, 50%, and 53%; P < .001). Race, diagnosis period, age, stage, and location of residence significantly predicted chemotherapy use. Females (51%), Asians (53%), and rural residents (60%) were more likely to receive chemotherapy. The median overall survival with and without chemotherapy was 9.6 and 3.6 months, respectively. Linear trend analyses showed a modest reduction in the impact of chemotherapy on survival for patients treated with chemotherapy versus untreated patients (hazard ratios [HRs], 0.59, 0.61, 0.64, and 0.62; P < .001) but an overall trend of improved survival for treated (HRs, 1.0, 1.03, 1.00, and 0.96; P = .005) and untreated patients (HRs, 1.0, 0.99, 0.94, and 0.92; P < .001). There was no survival difference between patients treated with carboplatin and patients treated with cisplatin (HR, 0.99; confidence interval [CI], 0.81-1.19; P = .875). Additional therapy beyond platinum-based chemotherapy was associated with a survival benefit (HR, 0.78; CI, 0.75-0.81; P < .001). CONCLUSIONS: Chemotherapy use was associated with a survival benefit in Medicare patients with SCLC treated in a real-world setting.
Keywords:
Medicare; Surveillance, Epidemiology, and End Results (SEER); predictors; small cell lung cancer (SCLC); survival; systemic therapy; trend analyses
Authors: Taofeek K Owonikoko; Camille Ragin; Zhengjia Chen; Sungjin Kim; Madhusmita Behera; Johann C Brandes; Nabil F Saba; Rebecca Pentz; Suresh S Ramalingam; Fadlo R Khuri Journal: Oncologist Date: 2013-05-01
Authors: Gregory P Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura Qm Chow; Robert J Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W Loo; Robert E Merritt; Cesar A Moran; Harvey B Niell; Janis O'Malley; Jyoti D Patel; Neal Ready; Charles M Rudin; Charles C Williams; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2013-01-01 Impact factor: 11.908
Authors: Frank Aboubakar Nana; Marylène Lecocq; Maha Zohra Ladjemi; Bruno Detry; Sébastien Dupasquier; Olivier Feron; Pierre P Massion; Yves Sibille; Charles Pilette; Sebahat Ocak Journal: Mol Cancer Ther Date: 2018-10-23 Impact factor: 6.261
Authors: Donna R Rivera; Clara J K Lam; Lindsey Enewold; Valentina I Petkov; Quyen Tran; Sean Brennan; Lois Dickie; Timothy S McNeel; Annie M Noone; Bradley Ohm; Dolly P White; Joan L Warren; Angela B Mariotto; Lynne Penberthy Journal: J Natl Cancer Inst Monogr Date: 2020-05-01
Authors: Portia L Thomas; Chioma J Madubata; Melinda C Aldrich; Montessa M Lee; Taofeek K Owonikoko; John D Minna; Charles M Rudin; Julien Sage; Christine M Lovly Journal: Cancer Discov Date: 2020-12-14 Impact factor: 38.272